|Year : 2017 | Volume
| Issue : 2 | Page : 87-89
Topical steroid-dependent face: Response to xylometazoline topical
Sushil Kakkar, Prafulla K Sharma
Department of Dermatology and STD, Dr. Ram Manohar Lohia Hospital and PGIMER, New Delhi, India
|Date of Web Publication||28-Dec-2017|
Dr. Sushil Kakkar
Department of Dermatology and STD, Dr. Ram Manohar Lohia Hospital and PGIMER, New Delhi
Source of Support: None, Conflict of Interest: None
Unsupervised and long-term use of fluorinated/potent topical steroids on the face can lead to side effects such as acne, skin thinning, photosensitivity, and a typical clinical presentation of a topical steroid-dependent face (TSDF) with rebound flushing, burning, dryness, and scaling on attempted withdrawal of the potent topical steroid cream. To evaluate the response of a commercially available nasal decongested solution of xylometazoline 0.05% in patients of long-term potent topical steroid abuse on the face. Two patients with a history of long-term, indiscriminate, and unsupervised topical steroid use on the face were asked to use a commercially available nasal decongestant solution, on face. Patients were asked to use the decongestant solution on face, once daily for 2 weeks. Follow-up after 2 weeks demonstrated excellent improvement in flushing and erythema. Side effects reported were transient tingling and stinging sensation. Xylometazoline, being an alpha-adrenergic agonist, presents an effective new option for treatment in patients of flushing and erythema, resulting from long-term topical steroid use on face.
Keywords: Red face, steroid induced, vasoconstriction, xylometazoline
|How to cite this article:|
Kakkar S, Sharma PK. Topical steroid-dependent face: Response to xylometazoline topical. Indian J Drugs Dermatol 2017;3:87-9
|How to cite this URL:|
Kakkar S, Sharma PK. Topical steroid-dependent face: Response to xylometazoline topical. Indian J Drugs Dermatol [serial online] 2017 [cited 2022 Nov 27];3:87-9. Available from: https://www.ijdd.in/text.asp?2017/3/2/87/221754
| Introduction|| |
While topical steroids are the most useful medication for ameliorating various inflammatory skin conditions, they are also the most misused or abused medications, particularly on face. The initial remarkable improvement in inflammatory skin conditions on face to a potent topical steroid almost certainly results in side effects, on long-term or repeated use. Topical steroid-dependent face (TSDF), i.e,. flushing or rebound erythema, burning, itching, and dryness/scaling is a commonly encountered complication on withdrawal of indiscriminate, long-term use of potent topical steroids on face, apart from other associated side effects such as acne, perioral dermatitis, and background erythema. This clinical picture is strikingly similar to rosacea. In addition to withdrawal of the offending potent topical steroid cream, treatment measures have been quite similar to rosacea - broad spectrum sunscreens, emollients, metronidazole, immunomodulators such as tacrolimus/pimecrolimus, oral tetracyclines, and macrolides have been used for steroid-induced rosacea-like dermatitis.
We report 2 patients with a history of long-term topical steroids use on face with side effects such as flushing, erythema, and acne, who responded very well to topical alpha-adrenergic agonist, xylometazoline.
Several papers have studied the effects of topical vasoconstrictors in the treatment of flushing and background erythema in rosacea. Brimonidine, xylometazoline, and oxymetazoline have been studied in this category. Brimonidine tartrate is a highly selective α2-adrenergic receptor agonist whose mechanism of action in the treatment of rosacea is thought to involve vasoconstriction of superficial skin vasculature and to a lesser extent anti-inflammatory effects. Successful treatment of flushing and background erythema with other topically applied adrenergic receptor modifiers such as oxymetazoline and xylometazoline have also been documented in the literature.
Therefore, drawing on literature reports about the use of alpha-adrenergic agonists in erythemotelangiectatic rosacea, we assumed the effectiveness of topical xylometazoline in treating steroid-induced rosacea-like dermatitis. Xylometazoline is commonly used in decongestant in nasal drops and sprays, for relieving nasal blockade.
| Case Reports|| |
A 32-year-old female, homemaker, was using betamethasone valerate 0.05% cream, for past 6 months, as a regular fairness cream, on a friend's advice. She noticed that over the past 2 months, her face had started to turn increasingly red, especially over the malar area, forehead, nose, as well as chin. She continued to use betamethasone valerate cream despite these side effects. Her skin started to burn and itch, especially when outdoors and when cooking food at home. On presentation, she complained of flushing and had diffuse and persistent redness on cheeks, forehead, and chin with few telangiectasia [Figure 1]a.
There was no history of oral ulcers, joint pains, and fever. She was ANA negative and her blood work was within normal limits. She was advised to stop topical steroid cream and asked to use a broad spectrum sunscreen (SPF 50) throughout the day and xylometazoline 0.05% solution, once daily at night. She complained of occasional transient stinging and tingling sensation on its use. On her next visit 2 weeks later, her skin erythema improved remarkably [Figure 1]b and the patient was then asked to discontinue xylometazoline solution, and on further follow-up at 4 weeks, her skin remained clear. There was no worsening of redness during this period.
An 18-year-old young female procured mometasone furoate 0.1% cream over the counter and was using this cream for acne on her face, on a friend's advice. She had continued using this cream for over 5 months because of initial good response in her inflammatory acne, however, was troubled by her face becoming sensitive and red. When she presented to us, she had diffuse redness on cheeks and inflammatory acne on cheeks along with burning and itching sensation [Figure 2]a.
She was asked to stop topical steroid cream and was started on clindamycin 1% gel and xylometazoline 0.05% solution, once daily at night for 2 weeks. Sun protection was advised. Her next follow-up at 2 weeks had a visible reduction in acne as well as erythema and flushing [Figure 2]b.
| Discussion|| |
TSDF presents a challenging problem for the patient as well as the treating dermatologist. Initially, patients may start using topical steroids for some trivial dermatosis like seborrheic dermatitis on advice by friends and relatives. At first, the vasoconstrictive and anti-inflammatory effects of the steroids result in what seems to be clearance of the primary dermatitis but repeated use leads to epidermal atrophy, degeneration of dermal structure, and collagen deterioration over several months. Multiple pathways including rebound vasodilatation and release of proinflammatory cytokines by chronic intermittent steroid exposure induce rosacea-like eruption.
A landmark, multicentric study in India, (Saraswat et al.), re-emphasized and documented that steroid dependence due to long-term and repeated topical steroid use is widely prevalent and also coined the term “TSDF” to connote typical features of long-term potent topical steroid abuse on face such as rebound erythema, burning, itching, and dryness/scaling.,,,,,,,,,,, Other important studies during that period also stressed on the fact that easy availability of potent topical steroids over the counter without a legitimate prescription needs to be stopped altogether, in consultation with policymakers and that would go a long way in ameliorating the problem of steroid misuse in principle. This among other things like the primary aim of educating and spreading awareness about the dangers of using steroid based creams without legitimate prescription or for more than the recommended duration, over the past decade, has been the focus of several distinguished authors (Saraswat et al., Coondoo, Rathi, Abraham and Roga, Dey, Coondoo et al.) of national association of dermatologists, venereologists, and leprologists in a developing country like India (IADVL), where the problem of topical steroid abuse on face is still rampant and a lot needs to be done in this direction.,,,,,
Recovery of TSDF is slow, and treatment requires patience, both on the part of the patient as well as the treating dermatologist. Apart from the discontinuation of topical steroid, which invariably leads to a flare-up of flushing and erythema, oral anti-inflammatory antibiotics, with or without topical metronidazole, and/or topical calcineurin antagonists such as tacrolimus and pimecrolimus, may be added.,,,
Recently, there has been an emphasis on newer medical therapies (alpha-adrenergic agonists such as brimonidine, xylometazoline, and oxymetazoline) in the treatment of rosacea with various studies and case reports highlighting their effectiveness in improving flushing and erythema of rosacea.,,,,,, Brimonidine 0.33% gel is also approved by the US-Food and Drug Administration for treatment of rosacea, apart from the other approved topical therapies (metronidazole, azelaic acid, sulfacetamide sodium, and recently, ivermectin). This urged us in our effort to find out the effectiveness of alpha-adrenergic agonists in patients with steroid-induced flushing and erythema. Excellent improvement and faster recovery to topical xylometazoline in 2 such patients furnish a new approach to treatment of these patients, acting by directly constricting the cutaneous vasculature thus reducing the blood flow, flushing and erythema and exerting anti-inflammatory effects.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patients have given their consent for their images and other clinical information to be reported in the journal. The patients understand that name and initials will not be published and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Litt JZ. Steroid-induced rosacea. Am Fam Physician 1993;48:67-71.
Sneddon I. Iatrogenic dermatitis. Br Med J 1969;4:49.
Ljubojeviae S, Basta-Juzbasiae A, Lipozenèiae J. Steroid dermatitis resembling rosacea: Aetiopathogenesis and treatment. J Eur Acad Dermatol Venereol 2002;16:121-6.
Saraswat A, Lahiri K, Chatterjee M, Barua S, Coondoo A, Mittal A, et al.
Topical corticosteroid abuse on the face: A prospective, multicenter study of dermatology outpatients. Indian J Dermatol Venereol Leprol 2011;77:160-6.
] [Full text]
Coondoo A. Topical corticosteroid misuse: The Indian scenario. Indian J Dermatol 2014;59:451-5.
] [Full text]
Abraham A, Roga G. Topical steroid-damaged skin. Indian J Dermatol 2014;59:456-9.
] [Full text]
Tempark T, Shwayder TA. Perioral dermatitis: A review of the condition with special attention to treatment options. Am J Clin Dermatol 2014;15:101-13.
Rathi S. Abuse of topical steroid as cosmetic cream: A social background of steroid dermatitis. Indian J Dermatol 2006;51:154-5
Dey VK. Misuse of topical corticosteroids: A clinical study of adverse effects. Indian Dermatol Online J 2014;5:436-40. [Full text]
Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: A long overdue revisit. Indian Dermatol Online J 2014;5:416-25. [Full text]
Leyden JJ, Thew M, Kligman AM. Steroid rosacea. Arch Dermatol 1974;110:619-22.
Sneddon I. Adverse effect of topical fluorinated corticosteroids in rosacea. Br Med J 1969;1:671-3.
Goldman D. Tacrolimus ointment for the treatment of steroid-induced rosacea: A preliminary report. J Am Acad Dermatol 2001;44:995-8.
Chen AY, Zirwas MJ. Steroid-induced rosacealike dermatitis: Case report and review of the literature. Cutis 2009;83:198-204.
Bhat YJ, Manzoor S, Qayoom S. Steroid-induced rosacea: A clinical study of 200 patients. Indian J Dermatol 2011;56:30-2.
] [Full text]
Rathi SK, Kumrah L. Topical corticosteroid-induced rosacea-like dermatitis: A clinical study of 110 cases. Indian J Dermatol Venereol Leprol 2011;77:42-6.
] [Full text]
Del Rosso JQ. Management of cutaneous rosacea: Emphasis on new medical therapies. Expert Opin Pharmacother 2014;15:2029-38.
Oge' LK, Muncie HL, Phillips-Savoy AR. Rosacea: Diagnosis and treatment. Am Fam Physician 2015;92:187-96.
Yin V. Acne and rosacea: Epidemiology, diagnosis and treatment. Australas J Dermatol 2014;55:240.
Lanoue J, Goldenberg G. Therapies to improve the cosmetic symptoms of rosacea. Cutis 2015;96:19-26.
Piwnica D, Rosignoli C, de Ménonville ST, Alvarez T, Schuppli Nollet M, Roye O, et al.
Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine. J Dermatol Sci 2014;75:49-54.
Kim JH, Oh YS, Ji JH, Bak H, Ahn SK. Rosacea (erythematotelangiectatic type) effectively improved by topical xylometazoline. J Dermatol 2011;38:510-3.
Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol 2007;143:1369-71.
[Figure 1], [Figure 2]